TABLE 3.
Summary of the conditions where emerging cannabinoids have been studied
| Cannabigerol (CBG)/derivatives | Cannabidivarin (CBDV) | Cannabichromene (CBC) | Cannabinol (CBN) | Cannabidiolic acid (CBDA) | ∆9‐THCV | ∆9‐THCA | |
|---|---|---|---|---|---|---|---|
| Huntington's | ✓ | ‐ | ‐ | ✓ | X | ‐ | ✓ PPARγ a |
| Multiple sclerosis | ✓ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
| Autoimmune encephalomyelitis | ✓PPARγ/CB2 a | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
| Parkinson's | ✓PPARγ a | ‐ | ‐ | ‐ | ‐ | ✓ | ✓ |
|
Neuroinflammation /neuroprotection |
✓ | ✓ | ✓ | ✓ | ‐ | ✓ | ✓ |
| Epilepsy/seizure | ✗ | ✓TRPV1 a | ✓ | ‐ | ‐ | ✓ | ‐ |
| Amyotrophic lateral sclerosis (ALS) | ✓ | ‐ | ‐ | ✓ | ‐ | ‐ | ‐ |
| Oxidative stress | ‐ | ‐ | ‐ | ✓ | ‐ | ‐ | ‐ |
| Rett syndrome | ‐ | ✓ | ‐ | ‐ | ‐ | ‐ | ‐ |
| Alzheimer's disease | ✓ | ✓ | ✓ | ‐ | ‐ | ‐ | ‐ |
Note. A tick or cross represents whether a cannabinoid showed efficacy in a condition or not. A dash means that a cannabinoid has yet to be studied in a condition.
a
Some of the compounds neuroprotective effects were mediated by this receptor, but no other receptors were probed.